GET DAILY SIGNALSWhy Is Alphatec Holdings (ATEC) Stock Down -4.10% Today?
Key Takeaways
- ATEC shares fell approximately 4.10% intraday, trading near $7.48 versus a prior-session close of $7.80.
- The decline extends a steep earnings-driven selloff that began after third-quarter results missed estimates and management cut full-year 2026 revenue guidance.
- Continued analyst downgrades and price-target reductions have added to the downward pressure.
- Shareholder-rights law firms have launched securities investigations, creating a persistent legal overhang on the stock.
- Broader weakness in the spine-medical-device space and ongoing questions about biologics attach rates are weighing on sentiment.
- Traders are watching for stabilization near the post-earnings lows and any further analyst or guidance revisions.
- For more information about this ticker, explore its Price Targets, Earnings, and Forecast pages.
- You can also explore Trending AI Robots to see AI-driven trading strategies currently active on this and other tickers.
Opening Summary
Alphatec Holdings, Inc. (ATEC), a medical device company focused on surgical solutions for spinal disorders, was trading lower in Thursday's session, down roughly 4.10% to about $7.48, compared with the prior close of $7.80. The move extends the stock's sharp post-earnings decline and reflects continued investor caution after disappointing third-quarter results, a lowered full-year outlook, a wave of analyst downgrades, and newly announced shareholder investigations.
Earnings Miss and Guidance Cut
The core catalyst for the stock's weakness traces back to ATEC's third-quarter report, in which adjusted earnings of $0.09 per share came in below consensus expectations and revenue of roughly $221 million narrowly missed forecasts. Management also reduced full-year 2026 revenue guidance to approximately $862 million, citing softer biologics attachment, a decline in revenue per case, and a slowdown in thoracolumbar procedure volumes. Notably, this marked the second guidance reduction in six months, eroding investor confidence in the company's near-term growth trajectory.
Analyst Downgrades and Price-Target Cuts
Sell-side reaction has compounded the selling pressure. Multiple firms lowered their ratings or price targets in the wake of the report, including downgrades to Neutral and Market Perform ratings alongside meaningful cuts to prior price objectives. The common theme across the revisions is reduced conviction in the timing of a return to historical 20%-plus revenue growth, with several analysts now modeling fiscal 2027 revenue, EBITDA, and free cash flow below the company's long-range plan. The cumulative effect has kept a lid on any recovery attempt.
Litigation and Regulatory Overhang
Adding to the negative sentiment, a number of shareholder-rights law firms have announced investigations into potential securities claims against Alphatec Holdings, generally focused on the company's disclosures and the guidance reductions tied to its recent earnings reports. While these are investigations rather than formal complaints, the legal headlines have contributed to the stock's fragile trading tone and have discouraged dip-buying despite the steep valuation reset.
Market Context and Trading Activity
The current decline follows a period of unusually heavy trading. Volume surged dramatically on the initial earnings selloff, far exceeding the stock's typical daily turnover, and remained elevated in subsequent sessions as the market repriced the shares. The stock's attempted rebound toward the $8 level in the following days failed to hold, and Thursday's slide took it back below that mark, reinforcing a pattern of lower highs. The move has largely diverged from broader equity indices, indicating that company-specific fundamentals and sentiment—not a broad market pullback—are driving the action.
What Comes Next for ATEC
Investors will be watching for signs that the company's biologics pull-through and procedure-volume trends stabilize, as management has pointed to strong underlying case volumes and record new-surgeon adoption as leading indicators. Upcoming earnings, management commentary on the fourth quarter, and any additional analyst revisions or legal developments will be key. Risks include the potential for further guidance adjustments, sustained weakness in higher-margin biologics, and continued market-share pressures in thoracolumbar procedures. The stock remains highly sensitive to headline risk given the current scrutiny from both the sell side and litigation-focused firms.
Trending AI Robots
Tickeron offers hundreds of AI trading bots that monitor thousands of tickers, but only the strongest performers under current market conditions are featured in its curated Trending AI Robots section. These bots vary by strategy, timeframe, performance metrics, and the symbols they trade, giving users a way to track AI-driven signals across changing market environments. Explore Trending AI Robots to see which automated strategies are currently showing strength.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
ATEC in upward trend: price may ascend as a result of having broken its lower Bollinger Band on October 30, 2026
ATEC may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 31 of 35 cases where ATEC's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 89%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where ATEC's RSI Oscillator exited the oversold zone, 31 of 37 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 84%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +13.27% 3-day Advance, the price is estimated to grow further. Considering data from situations where ATEC advanced for three days, in 266 of 317 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
The Aroon Indicator entered an Uptrend today. In 194 of 253 cases where ATEC Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 77%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 30, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ATEC as a result. In 65 of 93 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 70%.
The Moving Average Convergence Divergence Histogram (MACD) for ATEC turned negative on October 30, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In 30 of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at 70%.
ATEC moved below its 50-day moving average on October 30, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for ATEC crossed bearishly below the 50-day moving average on November 03, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 12 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ATEC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 39 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 64 (best 1 - 100 worst), indicating fairly steady price growth. ATEC’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 96 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: ATEC's P/B Ratio (-99.819) is very low in comparison to the industry average of (4.115). P/E Ratio (-10.986) is within average values for comparable stocks, (1.586). ATEC's Projected Growth (PEG Ratio) (91.200) is very high in comparison to the industry average of (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (1.980) is also within normal values, averaging (40.124).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ATEC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a holding company with interests in medical equipment and supplies
Industry MedicalNursingServices
Advertisement